Latest Insider Transactions at Eli Lilly & CO (LLY)
This section provides a real-time view of insider transactions for Eli Lilly & CO (LLY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ELI LILLY & Co to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ELI LILLY & Co's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 19
2019
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
89
+0.2%
|
$10,858
$122.13 P/Share
|
|
Feb 16
2019
|
Johna Norton EVP, Global Quality |
SELL
Payment of exercise price or tax liability
|
Indirect |
17
-20.73%
|
$2,074
$122.48 P/Share
|
|
Feb 16
2019
|
Johna Norton EVP, Global Quality |
BUY
Exercise of conversion of derivative security
|
Indirect |
48
+36.92%
|
-
|
|
Feb 15
2019
|
Enrique A Conterno SVP&Pres, LillyDiab & LillyUSA |
SELL
Open market or private sale
|
Direct |
25,000
-15.83%
|
$3,025,000
$121.0 P/Share
|
|
Feb 11
2019
|
Michael J Harrington Senior VP and General Counsel |
BUY
Bona fide gift
|
Indirect |
62,500
+50.0%
|
-
|
|
Feb 11
2019
|
Michael J Harrington Senior VP and General Counsel |
SELL
Bona fide gift
|
Direct |
62,500
-56.66%
|
-
|
|
Feb 04
2019
|
Melissa S Barnes Chief Eth/Cmpl Ofcr & SVP, ERM |
BUY
Grant, award, or other acquisition
|
Direct |
7,411
+21.65%
|
$889,320
$120.17 P/Share
|
|
Feb 04
2019
|
Enrique A Conterno SVP&Pres, LillyDiab & LillyUSA |
BUY
Grant, award, or other acquisition
|
Direct |
26,681
+14.45%
|
$3,201,720
$120.17 P/Share
|
|
Feb 04
2019
|
Stephen F Fry SVP, HR & Diversity |
BUY
Grant, award, or other acquisition
|
Direct |
19,404
+13.48%
|
$2,328,480
$120.17 P/Share
|
|
Feb 04
2019
|
Michael J Harrington Senior VP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
28,155
+18.23%
|
$3,378,600
$120.17 P/Share
|
|
Feb 04
2019
|
Johna Norton EVP, Global Quality |
BUY
Grant, award, or other acquisition
|
Direct |
2,958
+12.44%
|
$354,960
$120.17 P/Share
|
|
Feb 04
2019
|
David A Ricks President, Chair, and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
26,567
+14.81%
|
$3,188,040
$120.17 P/Share
|
|
Feb 04
2019
|
Aarti S. Shah SVP & CIDO |
BUY
Grant, award, or other acquisition
|
Direct |
5,939
+22.7%
|
$712,680
$120.17 P/Share
|
|
Feb 04
2019
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
BUY
Grant, award, or other acquisition
|
Direct |
15,619
+18.07%
|
$1,874,280
$120.17 P/Share
|
|
Feb 04
2019
|
Anne E. White EVP & Pres, Lilly Neuroscience |
BUY
Grant, award, or other acquisition
|
Direct |
7,246
+25.61%
|
$869,520
$120.17 P/Share
|
|
Feb 04
2019
|
Alfonso G Zulueta SVP & President, Lilly Int'l |
BUY
Grant, award, or other acquisition
|
Direct |
21,224
+23.84%
|
$2,546,880
$120.17 P/Share
|
|
Feb 04
2019
|
Joshua L Smiley |
BUY
Grant, award, or other acquisition
|
Direct |
9,954
+24.92%
|
$1,194,480
$120.17 P/Share
|
|
Feb 04
2019
|
Donald A Zakrowski SVP, Finance, & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
3,243
+32.97%
|
$389,160
$120.17 P/Share
|
|
Feb 04
2019
|
Myles O'Neill SVP & Pres., Mfg. Operations |
BUY
Grant, award, or other acquisition
|
Direct |
8,592
+17.45%
|
$1,031,040
$120.17 P/Share
|
|
Feb 04
2019
|
Myles O'Neill SVP & Pres., Mfg. Operations |
BUY
Grant, award, or other acquisition
|
Indirect |
4,635
+7.48%
|
$556,200
$120.17 P/Share
|
|
Feb 01
2019
|
Myles O'Neill SVP & Pres., Mfg. Operations |
SELL
Payment of exercise price or tax liability
|
Indirect |
1,491
-2.75%
|
$177,429
$119.86 P/Share
|
|
Feb 01
2019
|
Myles O'Neill SVP & Pres., Mfg. Operations |
BUY
Exercise of conversion of derivative security
|
Indirect |
3,221
+5.61%
|
-
|
|
Feb 01
2019
|
Melissa S Barnes Chief Eth/Cmpl Ofcr & SVP, ERM |
SELL
Payment of exercise price or tax liability
|
Direct |
1,492
-7.14%
|
$177,548
$119.86 P/Share
|
|
Feb 01
2019
|
Melissa S Barnes Chief Eth/Cmpl Ofcr & SVP, ERM |
BUY
Exercise of conversion of derivative security
|
Direct |
3,333
+13.75%
|
-
|
|
Feb 01
2019
|
Enrique A Conterno SVP&Pres, LillyDiab & LillyUSA |
SELL
Payment of exercise price or tax liability
|
Direct |
5,476
-4.0%
|
$651,644
$119.86 P/Share
|
|
Feb 01
2019
|
Enrique A Conterno SVP&Pres, LillyDiab & LillyUSA |
BUY
Exercise of conversion of derivative security
|
Direct |
12,222
+8.2%
|
-
|
|
Feb 01
2019
|
Stephen F Fry SVP, HR & Diversity |
SELL
Payment of exercise price or tax liability
|
Direct |
3,995
-3.66%
|
$475,405
$119.86 P/Share
|
|
Feb 01
2019
|
Stephen F Fry SVP, HR & Diversity |
BUY
Exercise of conversion of derivative security
|
Direct |
8,889
+7.53%
|
-
|
|
Feb 01
2019
|
Michael J Harrington Senior VP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,404
-4.29%
|
$524,076
$119.86 P/Share
|
|
Feb 01
2019
|
Michael J Harrington Senior VP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
12,778
+11.08%
|
-
|
|
Feb 01
2019
|
David A Ricks President, Chair, and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,485
-4.16%
|
$652,715
$119.86 P/Share
|
|
Feb 01
2019
|
David A Ricks President, Chair, and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,222
+8.49%
|
-
|
|
Feb 01
2019
|
Alfonso G Zulueta SVP & President, Lilly Int'l |
SELL
Payment of exercise price or tax liability
|
Direct |
4,364
-8.57%
|
$519,316
$119.86 P/Share
|
|
Feb 01
2019
|
Alfonso G Zulueta SVP & President, Lilly Int'l |
BUY
Exercise of conversion of derivative security
|
Direct |
9,722
+16.02%
|
-
|
|
Jan 31
2019
|
Alfonso G Zulueta SVP & President, Lilly Int'l |
SELL
Open market or private sale
|
Direct |
4,000
-8.84%
|
$480,000
$120.0 P/Share
|
|
Jan 22
2019
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
93
+0.21%
|
$10,881
$117.09 P/Share
|
|
Jan 22
2019
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
91
+1.1%
|
$10,647
$117.09 P/Share
|
|
Jan 22
2019
|
Ellen R Marram Director |
BUY
Grant, award, or other acquisition
|
Direct |
58
+0.1%
|
$6,786
$117.09 P/Share
|
|
Jan 22
2019
|
Jackson P Tai Director |
BUY
Grant, award, or other acquisition
|
Direct |
17
+0.03%
|
$1,989
$117.09 P/Share
|
|
Jan 22
2019
|
Karen Walker Director |
BUY
Grant, award, or other acquisition
|
Direct |
85
+28.72%
|
$9,945
$117.09 P/Share
|
|
Jan 17
2019
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
136,577
-0.06%
|
$16,116,086
$118.47 P/Share
|
|
Jan 16
2019
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
1,657
-0.0%
|
$193,869
$117.87 P/Share
|
|
Jan 15
2019
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
51,766
-0.04%
|
$6,056,622
$117.74 P/Share
|
|
Dec 17
2018
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
89
+1.09%
|
$9,612
$108.36 P/Share
|
|
Dec 17
2018
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
50
+0.08%
|
$5,400
$108.36 P/Share
|
|
Dec 17
2018
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
101
+0.23%
|
$10,908
$108.36 P/Share
|
|
Dec 17
2018
|
Karen Walker Director |
BUY
Grant, award, or other acquisition
|
Direct |
126
+50.0%
|
$14,490
$115.81 P/Share
|
|
Dec 10
2018
|
Myles O'Neill SVP & Pres., Mfg. Operations |
SELL
Open market or private sale
|
Indirect |
25,000
-17.74%
|
$2,825,000
$113.15 P/Share
|
|
Dec 04
2018
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
15,500
-0.01%
|
$1,844,500
$119.0 P/Share
|
|
Dec 02
2018
|
Anne E. White EVP & Pres, Lilly Neuroscience |
SELL
Payment of exercise price or tax liability
|
Direct |
3,306
-19.33%
|
$390,108
$118.64 P/Share
|